Syndax Pharmaceuticals (SNDX)

• Market cap: $993M
• 1 day: 4.43%
• 5 days: 11.18%
• 1 month: -11.50%
• 3 months: -11.77%
• 6 months: -41.98%
• Year to date: -18.04%
• 1 year: -44.36%
• 5 years: 5.77%
• 10 years: -3.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Employees: 184

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

208% more call options, than puts

Call options by funds: $19.4M | Put options by funds: $6.29M

48% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 60

29% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 28

10.31% more ownership

Funds ownership: 104.55% [Q3] → 114.85% (+10.31%) [Q4]

2% more funds holding

Funds holding: 210 [Q3] → 215 (+5) [Q4]

11% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 8 (-1) [Q4]

24% less capital invested

Capital invested by funds: $1.71B [Q3] → $1.3B (-$417M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $41 255% upside
• Avg. target: $45 287% upside
• High target: $51 342% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Anupam Rama 15% 1-year accuracy 9 / 61 met price target	255% upside $41	Overweight Maintained	20 Mar 2025
Citigroup Yigal Nochomovitz 12% 1-year accuracy 5 / 41 met price target	264% upside $42	Buy Maintained	4 Mar 2025
HC Wainwright & Co. Edward White 24% 1-year accuracy 36 / 149 met price target	342% upside $51	Buy Reiterated	4 Mar 2025